Castration-Refractory Prostate Cancer: New Drugs in the Pipeline

被引：13
|
作者：
Schrijvers, Dirk [1 ]
Van Erps, Peter [2 ]
Cortvriend, Jim [2 ]
机构：
[1] Ziekenhuisnetwerk Antwerpen Middelheim, Dept Hematooncol, B-2020 Antwerp, Belgium
[2] Ziekenhuisnetwerk Antwerpen Middelheim, Dept Urol, B-2020 Antwerp, Belgium
来源：
ADVANCES IN THERAPY | 2010年 / 27卷 / 05期
关键词：
castration-refractory prostate cancer; docetaxel; cabazitaxel; abiraterone acetate; angiogenesis modulators; vaccines; PHASE-II TRIAL; ABIRATERONE ACETATE; 2ND-LINE CHEMOTHERAPY; PLUS PREDNISONE; CLINICAL-TRIAL; DOCETAXEL; INHIBITOR; CYP17; MITOXANTRONE; THALIDOMIDE;
D O I：
10.1007/s12325-010-0038-1
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naive or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.
引用
收藏
页码：285 / 296
页数：12
相关论文
共 50 条
  • [21] Activity of Dutasteride Plus Ketoconazole in Castration-Refractory Prostate Cancer After Progression on Ketoconazole Alone
    Sartor, Oliver
    Nakabayashi, Mari
    Taplin, Mary-Ellen
    Ross, Robert W.
    Kantoff, Philip W.
    Balk, Steven P.
    Oh, William K.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (03) : E90 - E92
  • [22] Second line chemotherapy in patients with castration-refractory prostate cancer. From clinical studies to practice
    Alekseev, B. Ya
    Nyushko, K. M.
    Kaprin, A. D.
    ONKOUROLOGIYA, 2019, 15 (01): : 84 - 91
  • [23] Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer - Review of the literature
    Nelius, T.
    Rinard, K.
    Filleur, S.
    CANCER TREATMENT REVIEWS, 2011, 37 (06) : 444 - 455
  • [24] Effect of PEDF on survival and in vivo antitumor activities of low-dose chemotherapy in castration-refractory prostate cancer
    Gaines, Natalie
    Nelius, Thomas
    Gillen, Jessica
    Rinard, Katherine
    Lopez, Jose
    Hirsch, Jennifer
    Cobos, Everardo
    Reynolds, C. Patrick
    Filleur, Stephanie
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] NEW DESIGNER DRUGS FOR CASTRATION RESISTANT PROSTATE CANCER
    Sun, Carrie
    Tapadar, Subhasish
    Gaul, David
    Arnold, Rebecca
    Oyelere, Adegboyega
    Petros, John
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1191 - E1191
  • [26] PSA Surge/Flare-Up in Patients With Castration-Refractory Prostate Cancer During the Initial Phase of Chemotherapy
    Nelius, T.
    Filleur, S.
    PROSTATE, 2009, 69 (16): : 1802 - 1807
  • [27] A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC)
    Laplanche, A.
    Beuzeboc, P.
    Lumbroso, J.
    Massard, C.
    Plantade, A.
    Escudier, B.
    Di Palma, M.
    Bouzy, J.
    Haddad, V.
    Fizazi, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Effect of PEDF on survival and the in vivo antitumor activities of low-dose chemotherapy in castration-refractory prostate cancer
    Nelius, Thomas
    Pardue, Natalie
    Gillen, Jessica
    Rinard, Katherine
    Hirsch, Jennifer
    Cobos, Everardo
    Reynolds, C. Patrick
    Filleur, Stephanie
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [29] The atypical site of ureteral metastasis in a patient with castration-refractory prostate cancer. A clinical case and a review of literature
    Alekseev, B. Ya.
    Ivyushko, K. M.
    Kalpinsky, A. S.
    Vorobyev, N. V.
    Golovashchenko, M. P.
    Kaprin, A. D.
    ONKOUROLOGIYA, 2014, 10 (01): : 82 - 87
  • [30] Myelodysplastic Syndrome Related to Successful Treatment With177Lu-PSMA for Metastatic Castration-Refractory Prostate Cancer
    Racaru, Lavinia Vija
    Krim, Mehdi
    Rivet, Valerian
    Mourey, Loic
    Courbon, Pr Frederic
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (10) : 975 - 977
12345